📊 DNTH Key Takeaways
Is Dianthus Therapeutics, Inc. /DE/ (DNTH) a Good Investment?
Dianthus Therapeutics is a pre-revenue biotech company burning significant cash with minimal revenue generation ($2M annually) and operating losses of $177.9M, indicating an early-stage development company far from profitability. The company's -$129.1M operating cash flow and -$129.3M free cash flow demonstrate unsustainable cash burn rates despite holding $51.1M in cash, providing only ~5 months of runway at current burn rates. Fundamental profitability and growth metrics are severely negative, with no clear path to revenue generation evident.
Dianthus Therapeutics shows very weak current fundamentals, with minimal revenue, deeply negative operating and net margins, and heavy ongoing cash burn. The balance sheet is a clear strength because the company has substantial equity, strong liquidity, and no meaningful leverage, but the business remains dependent on converting R&D spending into future commercial progress.
Why Buy Dianthus Therapeutics, Inc. /DE/ Stock? DNTH Key Strengths
- Strong balance sheet composition with $493.4M stockholders' equity and minimal debt (0.00x debt/equity ratio)
- Adequate short-term liquidity with 13.32x current ratio and $51.1M cash position
- Elevated insider activity (9 Form 4 filings in 90 days) may indicate management confidence in pipeline
- Very strong liquidity with current and quick ratios of 13.32x
- Large equity base and low liabilities support balance-sheet resilience
- No meaningful long-term debt reduces financial distress risk
DNTH Stock Risks: Dianthus Therapeutics, Inc. /DE/ Investment Risks
- Severe cash burn of $129.1M annually with only ~5 months of cash runway remaining
- Negligible revenue ($2M) relative to operating expenses indicates company is far from commercialization
- Extreme negative operating margins (-8739.3%) and net margins (-7973.3%) reflect pre-commercial stage with no near-term profitability path
- Negative free cash flow of -$129.3M indicates company is consuming capital at unsustainable rates
- Extremely weak profitability, including operating margin of -8739.3% and net margin of -7973.3%
- Large negative operating cash flow and free cash flow indicate sustained cash burn
- Revenue base is negligible, so growth quality and business model durability remain unproven
Key Metrics to Watch
- Monthly cash burn rate and runway calculation
- Clinical trial progress and pipeline advancement milestones
- Revenue growth trajectory and any progress toward commercialization
- Changes in stockholders' equity and cash position quarter-over-quarter
- Quarterly operating cash burn relative to cash and equivalents
- Meaningful revenue growth and improvement in operating loss
Dianthus Therapeutics, Inc. /DE/ (DNTH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.32x current ratio provides a solid financial cushion.
DNTH Profit Margin, ROE & Profitability Analysis
DNTH vs Healthcare Sector: How Dianthus Therapeutics, Inc. /DE/ Compares
How Dianthus Therapeutics, Inc. /DE/ compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Dianthus Therapeutics, Inc. /DE/ Stock Overvalued? DNTH Valuation Analysis 2026
Based on fundamental analysis, Dianthus Therapeutics, Inc. /DE/ has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Dianthus Therapeutics, Inc. /DE/ Balance Sheet: DNTH Debt, Cash & Liquidity
DNTH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Dianthus Therapeutics, Inc. /DE/'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.55 indicates the company is currently unprofitable.
DNTH Revenue Growth, EPS Growth & YoY Performance
DNTH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $396.0K | -$13.7M | $-0.74 |
| Q2 2025 | $193.0K | -$13.7M | $-0.51 |
| Q1 2025 | $874.0K | -$13.7M | $-0.54 |
| Q3 2023 | $924.0K | -$4.9M | $-3.78 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Dianthus Therapeutics, Inc. /DE/ Dividends, Buybacks & Capital Allocation
DNTH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Dianthus Therapeutics, Inc. /DE/ (CIK: 0001690585)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DNTH
What is the AI rating for DNTH?
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 85% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DNTH's key strengths?
Claude: Strong balance sheet composition with $493.4M stockholders' equity and minimal debt (0.00x debt/equity ratio). Adequate short-term liquidity with 13.32x current ratio and $51.1M cash position. ChatGPT: Very strong liquidity with current and quick ratios of 13.32x. Large equity base and low liabilities support balance-sheet resilience.
What are the risks of investing in DNTH?
Claude: Severe cash burn of $129.1M annually with only ~5 months of cash runway remaining. Negligible revenue ($2M) relative to operating expenses indicates company is far from commercialization. ChatGPT: Extremely weak profitability, including operating margin of -8739.3% and net margin of -7973.3%. Large negative operating cash flow and free cash flow indicate sustained cash burn.
What is DNTH's revenue and growth?
Dianthus Therapeutics, Inc. /DE/ reported revenue of $2.0M.
Does DNTH pay dividends?
Dianthus Therapeutics, Inc. /DE/ does not currently pay dividends.
Where can I find DNTH SEC filings?
Official SEC filings for Dianthus Therapeutics, Inc. /DE/ (CIK: 0001690585) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DNTH's EPS?
Dianthus Therapeutics, Inc. /DE/ has a diluted EPS of $-4.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DNTH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Dianthus Therapeutics, Inc. /DE/ has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DNTH stock overvalued or undervalued?
Valuation metrics for DNTH: ROE of -32.9% (sector avg: 15%), net margin of -7,973.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DNTH stock in 2026?
Our dual AI analysis gives Dianthus Therapeutics, Inc. /DE/ a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DNTH's free cash flow?
Dianthus Therapeutics, Inc. /DE/'s operating cash flow is $-129.1M, with capital expenditures of $245.0K. FCF margin is -6,350.9%.
How does DNTH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7,973.3% (avg: 12%), ROE -32.9% (avg: 15%), current ratio 13.32 (avg: 2).